Shanghai Medicilon Inc.

On February 19, SIBP-A17, the second class I innovative antibody drug conjugate (ADC) independently developed by China National Pharmaceutical Group's Shanghai Institute of Biological Products, received a clinical trial approval notice from the National Medical Products Administration (NMPA).  The SIBP-A17 is intended for clinical trials in patients with advanced malignant solid tumors. Shanghai Medicilon Inc. (Medicilon), as a partner of Shanghai Institute of Biological Products, provides preclinical research services such as pharmacokinetics and safety evaluation for the research and development of SIBP-A17.  This is another successful case of Medicilon helping the rapid implementation of research and development results in the ADC field. Medicilon Antibody Drug Conjugate R&D Service Platform One-Stop Service Promotes Efficient Drug Research and Development Honest innovation drives the Shanghai Institute of Biological Products to continuously upgrade its products, and al...

  Recently, Xuanzhu Biopharmaceutical (Xuanzhu) and its wholly-owned subsidiary Beijing Xuanzhu Bio, obtained clinical trial approval for the double-antibody ADC drug KM501 (No.: 2023LP00278).  This product is suitable for the treatment of advanced/metastatic solid tumors with positive/expression, amplification or mutation of HER2, including related advanced tumors with low expression of HER2.  The drug is the world's first double-antibody ADC drug that completely knocks out fucose, and is expected to become the "Best in Class" drug. Shanghai Medicilon Inc. (Medicilon), as a partner of Xuanzhu, provided KM501 with GLP-compliant preclinical research services based on the Medicilon Antibody Development Service Platform, including pharmacokinetic studies and  safety evaluation . This has won time for Xuanzhu to advance the KM501 into clinical research as fast as possible. Medicilon Antibody Drug Conjugate (ADC) R&D Service Platform The whole process facilitates the ...

  Table of Contents Mechanism of Action of ADCs ADC Pharmacodynamic Evaluation ADC Pharmacokinetics Evaluation ADC Toxicokinetics and Safety evaluation Antibody-drug conjugates (ADCs)  are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer enhanced targeting of cancer cells along with reduced toxic side effects, making them an attractive prospect for the field of oncology.  An antibody-drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. As all these components affect the ADC performance in equal measure, their optimisation is essential for the development of successful conjugates. Download the brochure:  Medicilon’s one-stop ADC R&D services platform It has taken a while for this field to take off, but to date, over 100 ADCs are under clinical development. Since December 2021, after several decades o...